

CURRICULUM VITAE

Persönliche Daten

Name: Dr. med. Michael Kaczmarczyk
Adresse: Charité – Universitätsmedizin Berlin
Klinik für Psychiatrie und Psychotherapie
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin
michael.kaczmarczyk@charite.de
<https://psychiatrie.charite.de/>

Ausbildung und Tätigkeiten

01/2020 Berufung in die Kontroll- und Überprüfungscommission am IMPP –
Institut für medizinische und pharmazeutische Prüfungsfragen

seit 07/2019 BIH Charité Clinician Scientist Program

seit 05/2018 Fachvertretung – Psychiatrie und Psychotherapie
Klinik für Psychiatrie und Psychotherapie
Charité – Universitätsmedizin Berlin
Campus Benjamin Franklin

07/2017 – 06/2019 BIH Charité Junior Clinician Scientist Program

09/2016 Promotion zum Dr. med.
Dissertationsthema: „Effects of Fludrocortison-induced Stimulation of
Central Mineralocorticoid Receptors on Memory Function in
Depressed and Healthy Controls“
Betreuung: Prof. Dr. med. Christian Otte
Klinik für Psychiatrie und Psychotherapie
Charité – Universitätsmedizin Berlin
Campus Benjamin Franklin

seit 08/2015 Assistenzarzt und Wissenschaftlicher Mitarbeiter
Klinik für Psychiatrie und Psychotherapie
Charité – Universitätsmedizin Berlin
Campus Benjamin Franklin

2008 – 2015 Studium der Humanmedizin
Charité – Universitätsmedizin Berlin

Publikationen (Stand: 07/2020)

Nowacki J, Wingenfeld K, **Kaczmarczyk M**, Chae WR, Abu-Tir I, Deuter CE, Piber D, Hellmann-Regen J, Otte C. Cognitive and emotional empathy after stimulation of brain mineralocorticoid and NMDA receptors in patients with major depression and healthy controls. *Neuropsychopharmacology*. 2020;10.1038/s41386-020-0777-x. doi:10.1038/s41386-020-0777-x.

Nowacki J, Wingenfeld K, **Kaczmarczyk M**, Chae WR, Salchow P, Abu-Tir I, Piber D, Hellmann-Regen J, Otte C. Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression. *Transl Psychiatry* 10, 109 (2020). doi: 10.1038/s41398-020-0789-7.

Deuter CE, Wingenfeld K, Otte C, Bustami J, **Kaczmarczyk M**, Kuehl LK. Noradrenergic system and cognitive flexibility: Disentangling the effects of depression and childhood trauma. *J Psychiatr Res*. 2020 Apr 5;125:136-143. doi: 10.1016/j.jpsychires.2020.03.017.

Kaczmarczyk M, Spitzer C, Wingenfeld K, Wiedemann K, Kuehl Linn K., Schultebrucks K, Otte C. No association between major depression with and without childhood adversity and the stress hormone copeptin. *Pharmacopsychiatry* 53(2). March 2020. doi: 10.1055/s-0039-3403002.

Nowacki J, Chae WR, **Kaczmarczyk M**, Wingenfeld K, Otte C. Effects of mineralocorticoid receptor and NMDA receptor stimulation on stress hormone secretion in depressed patients and healthy individuals. *European Neuropsychopharmacology*, Volume 29, Supplement 6, December 2019, Pages 45-46. doi: 10.1016/j.euroneuro.2019.09.101.

Nowacki J, **Kaczmarczyk M**, Chae WR, Wingenfeld K, Otte C. Effects of mineralocorticoid receptor and NMDA receptor stimulation on empathy in depressed patients and healthy individuals. *Psychoneuroendocrinology*, Volume 107, Supplement, September 2019, Pages 23-24. doi: 10.1016/j.psyneuen.2019.07.066.

Kuehl LK, Deuter CE, Hellmann-Regen J, **Kaczmarczyk M**, Otte C, Wingenfeld K. Enhanced noradrenergic activity by yohimbine and differential fear conditioning in patients with major depression with and without adverse childhood experiences. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019 Aug 22;96:109751. doi: 10.1016/j.pnpbp.2019.109751.

Kaczmarczyk M, Otte C, Wiedemann K, Kuehl LK, Schultebrasucks K, Spitzer C, Wingenfeld K. Major depression and atrial natriuretic peptide: The role of adverse childhood experiences. *Psychoneuroendocrinology*. 2019 Mar;101:7-11. doi: 10.1016/j.psyneuen.2018.10.020.

Nowacki J, **Kaczmarczyk M**, Chae WR, Abu-Tir I, Salchow P, Wingenfeld K, Otte C. Cardiovascular risk in young patients with a depressive disorder. *Pharmacopsychiatry* 52(2). February 2019. doi: 10.1055/s-0039-1679164.

Kaczmarczyk M, Wingenfeld K, Kuehl LK, Otte C, Hinkelmann K. Childhood trauma and diagnosis of major depression: Association with memory and executive function. *Psychiatry Research*. 2018 Dec;270:880-886. doi: 10.1016/j.psychres.2018.10.071.

Kaczmarczyk M, Regen F, Heuser I, Bajbouj M, Hellmann-Regen J. Inhibition of monoamine oxidase activity by repetitive transcranial magnetic stimulation: implications for inter-train interval and frequency. *Eur Arch Psychiatry Clin Neurosci*. 2018 Dec 17. doi: 10.1007/s00406-018-0969-0.

Kaczmarczyk M, Otte C, Wingenfeld K, Kuehl LK, Hinkelmann K. Mineralocorticoid receptor and cognitive function in major depression. *European Neuropsychopharmacology*, Volume 27, Supplement 4, October 2017, Pages 546-547. doi: 10.1016/S0924-977X(17)31044-1.

Kaczmarczyk M, Wingenfeld K, Kuehl LK, Otte C, Hinkelmann K. Childhood adversity and diagnosis of major depression: Association with memory and executive function? *Psychoneuroendocrinology*, Volume 83, Supplement, September 2017, Page 42. doi: 10.1016/j.psyneuen.2017.07.351.

Kaczmarczyk M, Otte C, Hinkelmann K, Wingenfeld K, Kuehl LK. Effects of fludrocortisone administration on cognitive functions in depressed and in healthy subjects. *European Neuropsychopharmacology*, Volume 27, Supplement 1, March 2017, Pages 50-51. doi: 10.1016/S0924-977X(17)30121-9.

Kaczmarczyk M, Cosma N, Ludolph P, Regen F. Hyponatriämie und depressives Syndrom. *NeuroTransmitter*. 03/2017. doi: 10.1007/s15016-017-5902-7.

Kaczmarczyk M, Laqua L, Hellmann-Regen J, Heuser I, Regen F, Hahn E. Isotretinoin als ein „second hit“ bei Schizophrenie? *NeuroTransmitter*. 01/2017. doi: 10.1007/s15016-017-5840-4.

Laqua C, **Kaczmarczyk M**, Ahlers E, Regen F, Hahn E. (2016). Chloroquinassozierte psychotische Störung. *NeuroTransmitter*. 27. 37-40. doi: 10.1007/s15016-016-5417-7.

Otte C, Wingenfeld K, Kuehl LK, **Kaczmarczyk M**, Richter S, Quante A, Regen F, Bajbouj M, Zimmermann-Viehoff F, Wiedemann K, Hinkelmann K. Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals. *Neuropsychopharmacology*. 2015 Jan;40(2):386-93. doi: 10.1038/npp.2014.181.